Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL
2017
Early response to
induction chemotherapyis an important prognostic factor in B-
lymphoblasticleukemia (B-ALL). Here, we compare high-throughput sequencing (HTS) of IGH and TRG genes vs flow cytometry (FC) for measurable residual disease (MRD) detection at the end of
induction chemotherapyin pediatric patients with newly diagnosed B-ALL. Six hundred nineteen paired pretreatment and end-of-induction bone marrow samples from Children’s Oncology Group studies AALL0331 (clinicaltrials.gov #NCT00103285) (standard risk [SR]; with MRD by FC at any level) and AALL0232 (clinicaltrials.gov #NCT00075725) (high risk; with day 29 MRD
Keywords:
-
Correction
-
Source
-
Cite
-
Save
42
References
96
Citations
NaN
KQI